BioCryst stock: Q3 revenue rises as 2026 outlook climbs

Published on 11/10/2026 at 22:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioCryst stock draws attention after Q3 revenue and profit growth. The company raised its 2026 total revenue outlook while holding ORLADEYO guidance steady.

Q3 Results Raise Full-Year Outlook

BioCryst reported third-quarter revenue of 180.3 million US dollars and net income of 37.9 million US dollars.
ORLADEYO revenue reached 174.8 million US dollars, while the company maintained its full-year ORLADEYO outlook.
BioCryst raised full-year 2026 total revenue guidance and expects further savings from its Birmingham site closure.

BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals reported stronger third-quarter profitability on November 4, while raising its full-year 2026 total revenue outlook. The company said the quarter ended September 30 delivered continued ORLADEYO growth and progress in its rare-disease pipeline. The BioCryst release reported total revenue of 180.3 million US dollars, up 13 percent year over year.

ORLADEYO Remains Core Growth Driver

ORLADEYO revenue reached 174.8 million US dollars in the third quarter. BioCryst maintained its full-year global ORLADEYO revenue guidance of 625 million to 645 million US dollars. The company said the transition to CareMed as its sole-source specialty pharmacy partner supported distribution and patient access, while an initial inventory build contributed to quarterly revenue.

GAAP operating profit increased to 53.3 million US dollars from 29.6 million US dollars a year earlier. Net income rose to 37.9 million US dollars from 12.9 million US dollars. On a non-GAAP basis, operating profit was 86.5 million US dollars and net income was 71.1 million US dollars; these figures exclude items such as stock-based compensation and restructuring costs.

Higher Revenue Target, Lower Expense Range

BioCryst raised its full-year 2026 total revenue outlook to 715 million to 730 million US dollars from 690 million to 715 million US dollars previously. The company attributed the increase mainly to higher licensing revenue for navenibart rights and stronger international RAPIVAB orders. It also improved its non-GAAP operating expense outlook to 415 million to 425 million US dollars.

The Birmingham site closure is expected to generate annualized savings of 30 million to 35 million US dollars once fully realized. BioCryst said its pivotal navenibart program remains on track to report top-line results at six- and twelve-month endpoints in the third quarter of 2027, while initial BCX17725 data in Netherton syndrome are expected by the end of 2026.

BioCryst stock traded at 6.74 euros on Lang & Schwarz at 22:18 CET on Tuesday, November 10, 2026.